Background: Arterial hypertension is the largest single contributor to global mortality, and is poorly controlled in approximately 50% of patients despite lifestyle and pharmacologic interventions. Renal sympathetic hyperactivity is a key factor in the maintenance and progression of hypertension and randomized clinical trials have shown that catheter-based renal sympathetic denervation reduces blood pressure (BP) in patients with resistant hypertension. "Real world" data regarding the efficacy of this novel therapy are not available.
